JOURNAL OF NEURO-ONCOLOGY

JOURNAL OF NEURO-ONCOLOGY Journal

publication venue for

Outcomes of whole-brain radiation with simultaneous in-field boost (SIB) for the treatment of brain metastases. 147:117-123. 2020
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II). 144:303-311. 2019
A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. 129:281-288. 2016
Erratum to: Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases (vol 123, pg 103, 2015) 2015
Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases. 123:103-111. 2015
Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. 122:367-382. 2015
Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. 122:111-119. 2015
Intracranial control and radiographic changes with adjuvant radiation therapy for resected brain metastases: whole brain radiotherapy versus stereotactic radiosurgery alone. 120:657-663. 2014
A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. 110:111-118. 2012
Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors. 107:407-411. 2012
Patterns of electromagnetic activity recorded from neoplastic tissue 2011
Primary meningeal CNS lymphoma treated with intra-arterial chemotherapy and blood-brain barrier disruption. 90:329-333. 2008
A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. 90:229-235. 2008
A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. 88:353-357. 2008
Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. 84:293-296. 2007
Incidence of infusion plan alterations after angiography in patients undergoing intra-arterial chemotherapy for brain tumors. 78:157-160. 2006
Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. 78:99-102. 2006
Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumors. 61:35-44. 2003
Intra-arterial carboplatin and intravenous etoposide for the treatment of recurrent and progressive non-GBM gliomas. 56:79-86. 2002
Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report. 55:179-184. 2001
Hydroxyurea chemotherapy for unresectable or residual meningioma. 49:165-170. 2000
Lhermitte's sign as a presenting symptom of primary spinal cord tumor. 29:183-188. 1996
ATTEMPTED DOSE INTENSIFIED CYCLOPHOSPHAMIDE, ETOPOSIDE, AND GRANULOCYTE-COLONY-STIMULATING FACTOR FOR TREATMENT OF MALIGNANT ASTROCYTOMA. 24:285-292. 1995
COMPARISON BETWEEN BCNU AND PROCARBAZINE CHEMOTHERAPY FOR TREATMENT OF GLIOMAS. 15:257-263. 1993
EXTRANEURAL METASTASES IN EPENDYMOMA. 14:135-142. 1992
INTRA-ARTERIAL CISPLATIN FOR THE TREATMENT OF MALIGNANT GLIOMAS. 7:39-45. 1989

category

CLINICAL NEUROLOGY Web of Science Category
ONCOLOGY Web of Science Category

International Standard Serial Number (ISSN)

0167-594X

Electronic International Standard Serial Number (EISSN)

1573-7373

journal abbreviation

J NEURO-ONCOL